GMED earnings analysis
What we found in GMED's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Globus Medical reported a strong performance for Q1 2026, showcasing a notable increase in revenue and EPS compared to both the prior quarter and year. Total net sales rose by 27.0% to approximately $759.9 million, while diluted EPS improved by 107.4% to $1.12, exceeding market expectations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Exceeds Expectations
- Actual revenue for Q1 2026 rose to $759.9 million, surpassing estimates by 2.86%.
- Significant EPS Beat
- The diluted EPS stood at $1.12, beating the estimate of $0.92 by 21.74%.
- U.S. and International Sales Up
- U.S. net sales increased by 25% to $604.9 million; international sales rose by 35.6% to $155 million.
- Improved Gross Margin
- Gross margin improved to 30.8% in Q1 2026 from 32.7% in Q1 2025.
- Strong Operating Cash Flow
- Operating cash flow rose to $202.4 million, up from $177.3 million, reflecting a $25.1 million increase.
- Increased Investment in R&D
- R&D expenses rose by 10.4% to $36.5 million, highlighting commitment to innovation.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Rising Acquisition Costs
- Acquisition-related costs spiked by 503% to $6.4 million due to fair value changes.
- Increased SG&A Expenses
- Selling, general and administrative expenses grew by 22.6% to $297.8 million, driven by Nevro-related costs.
- Cash Flow Variability
- Investing activities saw a net outflow of $182.7 million, a significant increase from the prior year.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.12
- Gross margin
- 30.8%
- Segment
- Musculoskeletal Solutions
- Segment
- Enabling Technologies
What they said about what is next.
No explicit numeric guidance provided; management indicates continued growth expectations.
The filing reads better than the one before it.
What came before.
- 10-K · February 24, 2026
- Globus Medical reported a strong Q4 2025 quarter with revenue of $826.42M and GAAP diluted EPS of $1.28, reflecting margin expansion (gross margin 68.4%, operating margin 20.5%) and robust free cash flow of $202M in the…
- 10-Q · November 5, 2024
- Globus Medical reported strong Q3 results: net sales of $625,705,000 (Q3 2024) vs $383,639,000 (Q3 2023) and diluted EPS of $0.38 (Q3 2024) vs $0.01 (Q3 2023). Operating income widened to $48,098,000 in the quarter and…
- 10-Q · August 6, 2024
- Revenue jumped sharply to $629,691 (in thousands) in Q2 2024 versus $291,615 in Q2 2023 (a $338,076 increase), driven by the NuVasive merger, but margin pressure and elevated acquisition/amortization and operating costs…
- 10-Q · November 8, 2022
- Globus Medical reported Q3 net sales of $254,148,000, up 10.6% year-over-year from $229,721,000, with gross profit of $188,651,000 and operating income of $59,702,000. Diluted EPS was $0.47 (vs $0.45 in Q3 2021).…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GMED makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever